Improving care for patients with cardiac amyloidosis has emerged as one of the hottest topics in cardiology. Pfizer helped kickstart that trend in 2019 when it gained FDA approval for two separate medications for the rare, but potentially fatal disease. 

Private equity is becoming more and more influential in many healthcare specialties, including cardiology. This has prompted increased speculation about the impact such investments may have on patient outcomes.

Seeking to thwart transmission of communicable respiratory diseases among patients, visitors and staff, hospitals in a handful of states have reinstated masking mandates.

While GLP-1 drugs were originally developed to treat diabetes, researchers keep finding additional ways these medications can potentially benefit patients.

Prosecutors successfully argued that the patient would not have died if clinicians had ordered a routine CT exam. 

The policies cover a wide range of interventional therapies, including Shockwave Medical's IVL technology and intravascular ultrasound. 

Roche, one of the world’s largest pharmaceutical companies, will gain both oral and injectable assets as a result of this acquisition.

The deal could also include additional clinical and regulatory milestone payments in the years ahead.